acid tool compound acts potent selective competitive antagonist glycine site nmda produces ketaminelike rapid antidepressant effects animal models however unable cross bloodbrainbarrier reason unsuitable clinical result centrallypenetrant prodrug developed use humans studied clinical trials potential treatment major depressive addition antagonizing nmda receptor also acts potent inhibitor reuptake glutamate synaptic vesicles vesicular glutamate reuptake inhibitor action mediates via competitive blockade vesicular glutamate transporters ki